Skip to content
Research Article Open access CC BY 4.0

Significance of Tumor Marker CA15-3 in Metastatic Breast Cancer

Hoor Fatima, Amir Maqbool, Marium Siddiqui, Ghulam Haider, Habiba Sohail, Omema Saleem, Afarina Ahmed

Journal of Cancer and Tumor International · pp. 1–12 · Published 18 Oct 2016

10.9734/JCTI/2016/28440

Abstract

Secondary spread of cancer to bones is commonest and frequent phenomenon and enhances the need of special care for sufferers. Bone metastases mostly are the first complication of different variety of cancers which increase the need of care and expensive facilities. Blood dissemination is another common route, might be due to the venous drainage from visceral organs directly into the axial bones. CA 15-3 is a mucinous tumor markers derived from MUC1 gene, provides better guide line about the treatment, recurrence and prognosis. Aim: Aim of the study was to signify the role of tumor marker CA15-3 in metastatic breast cancer. Methods: Hundred females of breast cancer (any age) with different stages of breast cancer with and without bone metastasis were tested for their serum level of CA 15-3 (biomarker of breast cancer). Bone scan was done to check the secondary metastasis to bones. Intravenous dye Ttechnicium 99 MDP has been used. Serum levels of ca15-3 were measured with the help of Gama Counter with computerized system and IRMA kit (Immunoradiometric Assay) by IMMUNOTECH. Ultrasound of whole abdomen and X ray/CT scan were used to detect liver and pulmonary metastasis respectively. Results: Results indicate a high statistical significant relationship between bone metastasis and elevated levels of tumor marker CA 15-3 in breast cancer patients. Elevated levels of tumor marker CA 15-3 is strongly correlated with positive bone scan. An elevated level of tumor marker CA 15-3 is also correlated with positive pulmonary metastasis CA 15-3 is highly sensitive to detect bone metastasis and also sensitive to detect pulmonary metastasis. A lesser extent of high CA 15-3 serum levels is determinant of liver metastasis. Bone scan is essential tool to detect bone metastasis but need assistance of chemical biomarkers. Conclusions: CA 15-3 as a tumor marker proved a help full determinant of tumor burden in metastatic breast cancer. Its significance is more to detect bone metastasis than to pulmonary and then to liver metastasis. Future studies upon CA15-3 in association with imaging techniques and other organ related specific tumor markers to detect specific metastasis or overall body tumor burden will be blessing for patients and physicians.  

Tumor marker CA15-3 bone liver and lung metastasis bone scan breast cancer

References (37)

  1. 1 Global Cancer Statistics, 2002 [DOI]
  2. 2 Mechanisms of Bone Metastasis [DOI]
  3. 3 Structure and Function of the Cell Surface (Tethered) Mucins [DOI]
  4. 4 The 2010 NCCN Clinical Practice Guidelines in Oncology on Prostate Cancer [DOI]
  5. 5 MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches [DOI]
  6. 6 Radionuclide Bone Imaging: An Illustrative Review [DOI]
  7. 7 Bisphosphonates: Clinical Experience [DOI]
  8. 8 INCIDENCE, LOCATION, AND DIAGNOSTIC EVALUATION OF METASTATIC BONE DISEASE [DOI]
  9. 9 High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients [DOI]
  10. 10 CA 15–3: A Prognostic Marker in Breast Cancer [DOI]
  11. 11 THE RÔLE OF THE VERTEBRAL VEINS IN METASTATIC PROCESSES [DOI]
  12. 12 Assessment of response to therapy in advanced breast cancer [DOI]
  13. 13 MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17 [DOI]
  14. 14 International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)–MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer [DOI]
  15. 15 CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer [DOI]
  16. 16 Individual differences in well-being in older breast cancer survivors [DOI]
  17. 17 Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease [DOI]
  18. 18 Clinical significance of solitary rib lesions in patients with extraskeletal malignancy.
  19. 19 Skeletal metastases of melanoma: radiographic, scintigraphic, and clinical review [DOI]
  20. 20 Vaccination with a Mixed Vaccine of Autogenous and Allogeneic Breast Cancer Cells and Tumor Associated Antigens CA15-3, CEA and CA125 - Results in Immune and Clinical Responses in Breast Cancer Patients [DOI]
  21. 21 Prognostic role of CA15.3 in 7942 patients with operable breast cancer [DOI]
  22. 22 Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index [DOI]
  23. 23 Serum peptidome patterns of breast cancer based on magnetic bead separation and mass spectrometry analysis [DOI]
  24. 24 CA 15-3 (Mucin-1) and Physiological Characteristics of Breast Cancer from Lahore, Pakistan [DOI]
  25. 25 Molecular Biomarkers for Breast Cancer Prognosis: Coexpression of c-erbB-2 and p53 [DOI]
  26. 26 Association between number and sites of new bone scan abnormalities and presence of skeletal metastases in patients with breast cancer.
  27. 27 PERIOPERATIVE CONSIDERATIONS IN PATIENTS WITH METASTATIC BONE DISEASE [DOI]
  28. 28 Risk of metastasis among rib abnormalities on bone scans in breast cancer patients [DOI]
  29. 29 The detection of skeletal metastases from mammary cancer. A regional comparison between radiology and scintigraphy [DOI]
  30. 30 Serum Markers and Prognosis in Locally Advanced Breast Cancer [DOI]
  31. 31 Third consensus on medical treatment of metastatic breast cancer [DOI]
  32. 32 Bone scans with one or two new abnormalities in cancer patients with no known metastases: frequency and serial scintigraphic behavior of benign and malignant lesions. [DOI]
  33. 33 Implications of the 99mTc diphosphonate bone scan on treatment of primary breast cancer.
  34. 34 Pain as an indicator of bone metastasis [DOI]
  35. 35 Prognostic evaluation in geriatric oncology: problems and perspectives [DOI]
  36. 36 [Accumulation of gene alterations and progression of breast cancer].
  37. 37 The aetiology of solitary hot spots in the ribs on planar bone scans [DOI]

Cited by 2

Clinical, Histopathological, and Biomarker Predictors of Bone Scintigraphy Positivity in Breast Cancer: A Retrospective Study

Andrew Soerijadi, Ryan Reinardi Wijaya, Achmad Hussein Sundawa Kartamihardja · World Journal of Nuclear Medicine · 2026

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

36

Page views

0

PDF downloads

5

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.